Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

NCT01089751 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT01089751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01089751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
Lead sponsor
Allergan
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2010
Completion date
June 30, 2012
Enrollment
322 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder